Cite
HARVARD Citation
Oyelakin, A. et al. (2022). EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC. NAR cancer. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Oyelakin, A. et al. (2022). EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC. NAR cancer. p. . [Online].